Beyond Air (XAIR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Special Meeting scheduled for June 18, 2026, to vote on a reverse stock split and potential adjournment if more time is needed for proxy solicitation.
The reverse stock split aims to increase the share price to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting.
The Board has discretion to set the split ratio between 1-for-2 and 1-for-20 at any time within one year of the meeting.
If delisted from Nasdaq, shares may trade OTC, which carries higher risks and reduced liquidity.
The Board recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1: Approve an amendment to effect a reverse stock split at a ratio of 1-for-2 to 1-for-20, at the Board's discretion.
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes for Proposal 1.
Both proposals require a majority of shares present or represented by proxy to pass.
No other proposals will be presented at the meeting.
Board of directors and corporate governance
The Board has full discretion to determine if and when to implement the reverse split within one year of approval.
Board members and executive officers are listed with their beneficial ownership in the proxy.
The Board may abandon the reverse split if it is no longer deemed in the best interests of the company.
Latest events from Beyond Air
- Tankless nitric oxide therapy platform drives rapid growth and global market expansion.XAIR
Corporate presentation - Generation 2 device approval is set to unlock a $400M+ market with immediate deployment planned.XAIR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Up to 5.4M shares registered for resale after a $10.2M private placement; focus on LungFit® growth.XAIR
Registration filing - Flat revenue, improved margins, and strong outlook depend on FDA approval and new product launch.XAIR
Q1 2027 - Revenue up 107% to $7.7M; Gen 2 launch and approval expected to drive major growth in 2027.XAIR
Q4 2026 - Shareholders will vote on a reverse stock split to maintain Nasdaq listing and avoid delisting risks.XAIR
Proxy filing - Patented tankless NO technology drives rapid growth and pipeline expansion in respiratory and oncology markets.XAIR
Corporate presentation - Q3 revenue up 105% YoY, net loss narrowed, and global expansion continues.XAIR
Q3 2026 - Next-generation system and global partnerships position the company for accelerated growth by 2027.XAIR
Piper Sandler 36th Annual Healthcare Conference